Human neutralizing autoantibodies to IFN-gamma underlying mycobacterial diseases
Active Grant Awarded
- Award ID
- R21AI193802
- Recipient
-
The University Of Texas Southwestern Medical Center UEI YZJ6DKPM4W63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $281,500
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 16% complete
- Place of performance
- Dallas, TX 75390, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $281,500 to The University of Texas Southwestern Medical Center on July 29, 2026, under Grant R21AI193802, funded through Allergy and Infectious Diseases Research (CFDA 93.855). The grant funds research testing whether tuberculosis, at least in some patients, is caused by interferon-gamma (IFN-γ) neutralizing autoantibodies with lower titer, lower affinity, or more transient presence than the autoantibodies linked to the autoimmune phenocopy of mendelian susceptibility to mycobacterial disease. A pilot cohort of 97 TB patients with known HLA type yielded four patients with neutralizing IFN-γ autoantibodies, present at lower titers. Work is performed in Dallas, Texas 75390, with the ultimate completion date of July 31, 2028.
The recipient issued a federal grant sub-award dated September 25, 2026 (R21AI193802-GMO 260811) to Texas Biomedical Research Institute, doing business as Southwest Foundation for Biomedical Research. The Ippolito Lab will analyze the IFN-γ-specific IgG repertoire in a defined cohort of tuberculosis patients (Specific Aim 3) using BCR-Seq and Ig-Seq, including sequencing of Ig genes from memory B cells, plasmablasts, and purified plasma IgG. The sub-recipient will express the most expanded monoclonal antibodies, assess IFN-γ binding by ELISA, and measure antibody affinity by Bio-Layer Interferometry. Rockefeller University will supply recombinant IFN-γ and evaluate neutralizing activity by luciferase assay. The deliverables include reports on IGHV, IGHD, and IGHJ gene usage and CDR-H3 properties of the circulating IFN-γ-specific IgG repertoires.
Description
- Abstract
- TB, caused by the more virulent mycobacterium tuberculosis (MTB), is a life-threatening mycobacterial disease that affects more than 10 million individuals and causes 1.5 million deaths annually, making IT the leading cause of death from a single infectious agent. A quarter of the world's population is estimated to be infected MTB, yet only 5-10% of infected individuals develop clinical disease. Despite being one of the most devastating diseases in human history, the pathophysiology of TB remains elusive. Prior studies of mendelian susceptibility of mycobacterial disease (MSMD), a rare condition marked by a selective vulnerability to weakly virulent environmental mycobacteria (EM) identified interferon-Γ (IFN-Γ) as essential for antimycobacterial immunity. TB patients without familial MSMD history carry mutations in these genes, impairing-but not completely abolishing-IFN-Γ-dependent antimycobacterial immunity. Thus, IFN-Γ serves as a quantitative trait influencing the outcome of mycobacterial infection. Neutralizing IFN-Γ autoantibodies (AUTO-ABS) can predispose individuals carrying HLA-DRB1*15:02 and/or HLA-DRB1*16:02 alleles to infections with EM thus providing an autoimmune phenocopy of MSMD. Although discovered two decades ago, the IFN-Γ AUTO-AB repertoire remains poorly understood, and while this autoimmune phenocopy underlies 1-5% of MSMD cases, no AUTO-ABS to IFN-Γ have been found in TB patients to date. Thus, we hypothesize that TB, at least in some patients, is caused by IFN-Γ AUTO-ABS with lower titer and/or lower affinity and/or transiently than AUTO-ABS described as casual to the autoimmune phenocopy of MSMD. Preliminary results from a pilot cohort of 97 TB patients of a known HLA type revealed four patients with neutralizing AUTO-ABS to IFN-Γ. Notably, these AUTO-ABS were present at lower titers, when compared with those observed in patients with infections due to EM. Therefore, the aim of this proposal is to expand upon this initial pilot cohort and to determine whether the neutralizing AUTO-ABS to IFN-Γ are causal in a proportion of TB cases. We also hypothesize that the nature of these pathogenic AUTO-ABS underlying TB may be transient and/or in lower quantity and/or lower affinity relative those underlying disease due to infections with EM. We will also investigate the molecular composition and epitopes of the IFN-Γ-specific IGG repertoire from patients known to harbor these pathogenic AUTO-ABS. Overall, the proposed study will provide novel and unique insights into the mechanisms by which a narrow autoimmunity can paradoxically underlie TB in some ("immunity autoimmunity"). Therefore, we propose a shift in the current understanding of TB in some-reframing IT not solely as an infectious disease, but as one that, in part, may arise from autoimmune disruption of IFN-Γ immunity. IT will also facilitate precision medicine, in terms of diagnosis and counselling, as well as prevention and treatment.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Texas Biomedical Research Institute | $99,000 |
Quick answers
Who received award R21AI193802?
R21AI193802 was awarded to The University Of Texas Southwestern Medical Center by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 29, 2026.
How much is award R21AI193802 worth?
$281,500 has been obligated on R21AI193802.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award